New hope for stomach cancer: experimental drug BHB810 enters human trials
NCT ID NCT07529808
First seen Apr 14, 2026
Summary
This study tests a new drug, BHB810, in adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. The drug is given as an IV infusion every two weeks. The main goals are to check safety and find the best dose, while also seeing if it can shrink tumors. About 164 people will take part in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.